Once-daily semaglutide 25 mg or 50 mg is superior to 14 mg for glycemic control among adults with type 2 diabetes, according to a study published online June 25 in The Lancet.
Vanita R. Aroda, M.D., from Brigham and Women’s Hospital in Boston, and colleagues conducted a global, multicenter, randomized phase 3b trial at 177 sites in 14 countries involving adults with type 2 diabetes. Participants had glycated hemoglobin (HbA1c) of 8.0 to 10.5 percent and body mass index of 25.0 kg/m2 or greater and were receiving stable daily doses of one to three oral glucose-lowering drugs. Participants were randomly assigned to 68 weeks of once-daily oral semaglutide 14 mg, 25 mg, or 50 mg (536, 535, and 535 participants, respectively). Change in HbA1c from baseline to week 52 was evaluated as the primary end point.
The researchers found that the mean changes in HbA1c at week 52 were −1.5, −1.8, and −2.0 percentage points with oral semaglutide 14 mg, 25 mg (estimated treatment difference, −0.27), and 50 mg (estimated treatment difference, −0.53), respectively. Adverse events were reported by 76, 79, and 80 percent of participants in the 14-mg, 25-mg, and 50-mg groups, respectively.